4 Analysts Have This To Say About Guardant Health
Portfolio Pulse from Benzinga Insights
Recent analyst ratings for Guardant Health (NASDAQ:GH) show a mix of bullish and somewhat bullish opinions, with a notable decrease in the average 12-month price target from $49.00 to $41.00, a 16.33% drop. Analysts from JP Morgan, Canaccord Genuity, and Goldman Sachs have lowered their price targets, reflecting adjustments to market dynamics and company performance. Guardant Health, a leader in liquid-based cancer tests, has shown impressive revenue growth of 21.83% as of September 30, 2023, but struggles with profitability and high debt levels.
February 23, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Guardant Health has received mixed analyst ratings with a lowered average price target of $41. Despite strong revenue growth, concerns about profitability and high debt may impact investor sentiment.
The decrease in the average price target by analysts, coupled with concerns about profitability and high debt levels, suggests a negative short-term impact on GH's stock price. However, the company's strong revenue growth could mitigate some negative perceptions.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100